Medical Evidence Generation Lead (MEGL) Northern Europe

at  Sanofi US

1. Generation of medical evidence that is supportive of, and aligned with business priorities for our vaccines in Belgium & Luxemburg

Lead the development & endorsement of the North European MEG strategy and operational plan, with a focus on preparing launches, supporting market access and expansion, demonstrating the continued value of our licensed vaccines, in alignment with Belgian & Luxemburg Medical Plans and Global MEG Strategies

• Working closely with Country Medical Leads for Vaccines in Belgium
• Collaborating with the Global Medical Franchise MEG teams to ensure alignment with the Global Brand strategy
• Focusing on identification of key gaps in evidence required to support development and business strategies
• Offering support to the development of Global Medical Franchise MEG strategies
• Integrating the insights obtained from engagement with external partners, investigators as well as funding organizations in strategy and operational plan development
• Maximizing the value of medical evidence by ensuring that the operational plan combines scientific excellence with novel evidence generation approaches as well as external insights and contributions
• Obtaining support and budget for the operational plan from local medical management and Global stakeholders.

1. Driving the timely execution of the MEG operational plan.

The MEGL leverages internal expertise and external partnerships to promote agile and efficient implementation of the activities and studies.

• The MEGL oversees the MEG budget
• The MEGL is accountable for efficient and timely execution of the operation plan
• Collaborating with Internal Medical Operations to ensure appropriate governance, compliance, and resourcing (internal and external)
• Ensuring study methodology meets highest quality standard for internal and external recognition. This entails both internal reviews and external stakeholders and experts engagement
• Monitoring study conduct in close collaboration and mitigating issues arising in execution and analysis
• Coordinating the interpretation and critical evaluation of study results, and participating in study results dissemination

1. Supporting the generation of medical evidence in other North European countries

• The MEGL will also support gradually over time the execution of other North European operational plans in alignment with the Global Medical Franchise MEG teams.

1. Participating in external scientific engagement

• The MEGL maintains a network of external experts, including among academic and public health institutions
• for advice, guidance and resource for evidence generation strategy and execution
• for insights in public health/scientific trends and needs
• The MEGL supports and attends as needed stakeholder meetings with NRAs and recommending bodies to support business and public affairs strategy with scientific & medical evidence
• The MEGL supports and participates in communication of scientific and medical evidence (eg.: congresses, internal & external training)